322 Index Name Paper ref. Name Paper ref. Caron, MG FC11.4.1, Wed 423 Carpino, F Tue 249 Carral, N Tue 197 Carrara, M Wed 320 Carraro, R Tue 134 Carrasco, VH Tue 326 Carrasco-Portugal, M Mon 009, Mon 019 Carreño, P Thu 187 Carroll, P Tue 309 Cars, Otto PL12 Cartwright, C Mon 351, Tue 353 Carvajal, A Mon 129, Mon 130 Carvalheiro, H Tue 397 Carvalho, DM Mon 010 Carvalho, L Wed 341 Carvalho, LCRM Wed 340 Carvalho, MH Wed 042 Carvalho, MHC FC06.1.5, Wed 237 Casadesus, G Mon 443 Casanova, M Thu 358 Casarin, E Wed 320 Casarotto, P FC17.5.5 Casas, M FC14.4.5 Cascorbi, I FC02.4.3, Mon 059 Casey-Green, K Mon 352, Mon 353 Cash, C Thu 394 Casolini, P Tue 249 Cassali, GD Wed 302 Cassano, T Thu 440 Castañeda-Hernández, G Mon 011, Mon 019 Castanheira, L Mon 126, Thu 218 Castel-Branco, MM Mon 376 Castells, X FC14.4.5 Castelo-Branco, M Thu 218 Castillo, I Tue 420 Castillo, MD Tue 326 Castillo, N Thu 225 Castro, E Wed 401, Thu 408 Castro, N Mon 398 Cataneo, SC Wed 332 Catanozi, S Wed 203, Mon 257 Cathala, C Mon 084 Catic-Djordjevic, A Tue 149 Catterall, WA FC12.1.2, Tue 479 Cavaleiro, C Tue 257 Cavun, S Mon 156, Wed 179 Cazzolla, N Mon 296, Thu 433 Ccalleja, G Tue 302 CCB Tue 281 Ceccelli, R Thu 237 Cekic, EG Mon 419, Wed 253 Cekic, V Wed 321 Celikyurt, IK Mon 387, Tue 145 Cellier, C W02.2.6 Ceman Saric, J Wed 171 Centurión, D W13.3, Thu 022, Thu 203 Ceravolo, GS FC06.1.5, Wed 042, Wed 233, Wed 237 Cercas, E Tue 134 Cerná, O Mon 267 Cernecka, H Mon 219 Cervantes-Nevárez, A Mon 019 Cervenka, R Mon 217, Mon 218 Ceverie, J Tue 370 Cha, E-Y Tue 351 Chadha, R Tue 344 Chadwick, B Tue 139 Chai, L Wed 322 Chaisri, S Thu 335 Chalian, M Thu 006 Challiss, RAJ Wed 030, Wed 025 Chalmers, RTA Thu 420 Chalon, S Tue 012 Chalopin, M Wed 216, Tue 118 Chamorro, G Wed 217 Champagne, M Wed 123 Chan, A W10.3 Chan, CKY Wed 218 Chan, C-M Tue 374 Chan, Elsa Mon 194, Wed 219 Chan, HC Thu 341 Chan, K Wed 292, Wed 220 Chan, M-H FC17.1.5, Mon 354 Chan, MLY Wed 290 Chan, P Mon 465, Tue 155 Chan, PF Wed 323 Chandra, V FC18.4.1 Chandranipapongse, W Mon 355 Chang, C FC15.2.5 Chang, C-Z Mon 319 Chang, H-C Tue 398 Chang, HH Mon 356 Chang, H-H Wed 286 Chang, J Mon 443 Chang, L-Y Thu 199 Chang, W-C Wed 368 Changkija, B Wed 294 Chanthap, L Tue 090 Chantratita, W Tue 127 Chao, PL Mon 325 Chaouch, W Wed 316 Chappell, M Mon 151 Charbeneau, R Thu 044 Charoin, J-E FC07.2.5 Charpentier, G Mon 161 Chartier-Kastler, E Mon 233, Mon 232 Chataigneau, T Wed 306, Wed 273, Wed 385 Chatsiricharoenkul, S Mon 334, Mon 357, Tue 007, Tue 341 Chatterjee, P Mon 157 Chatterjee, S FC14.2.3 Chatterjee, SS Wed 324, Wed 325 Chatzimichael, A Tue 224 Chaudhary, J Tue 020 Chauhan, NK Mon 195, Mon 237, Wed 425 Chaves, M Wed 318, Wed 319 Chávez, LB Tue 302 Chavkin, C FC14.4.4 Chefer, V FC03.3.1 Chekina, K Wed 100 Chelarescu, D Thu 175, FC14.2.6 Chen, AF FC15.1.2, FC15.4.6, W04.2.2 Chen, B Thu 384 Chen, B-C Mon 326 Chen, B-R Tue 146 Chen, C FC05.3.6 Chen, C-T Mon 012, Mon 158, Wed 262 Chen, CX Wed 291
Name Paper ref. Name Paper ref. Chen, D W02.2.1 Chen, FH Wed 291 Chen, G Thu 276 Chen, H Mon 185, Chen, H-H Mon 268, Mon 354 Chen, H-Z Tue 399 Chen, H Wed 221 Chen, H-H FC17.1.5 Chen, H-Z Thu 368 Chen, I-J Mon 269, Thu 105 Chen, I-S Thu 105 Chen, J Wed 331, Chen, J-C Wed 326 Chen, K Wed 366, Wed 365 Chen, K-H FC12.3.5 Chen, L Thu 390, Tue 400 Chen, LH Thu 295 Chen, L Tue 401 Chen, M Mon 045 Chen, M-F Thu 090, Thu 362, Wed 286 Chen, M-S Mon 186, FC09.5.6 Chen, N Wed 331, Wed 013, Wed 193 Chen, P Wed 072 Chen, PS Mon 356 Chen, P-Y Wed 286, Thu 090 Chen, S Wed 122, Wed 121, Wed 120 Chen, S-F Thu 277 Chen, S-H Mon 270 Chen, S-J Wed 222, Thu 283 Chen, S-S Mon 268 Chen, T-Y Wed 439 Chen, W-L FC16.4.5 Chen, X Tue 412, Wed 327, Thu 104 Chen, XH Tue 439 Chen, Y Tue 069 Chen, Y-H Wed 106 Chen, Y-C Tue 402 Chen, Y-F Wed 328 Cheng, G Mon 310, Mon 032 Cheng, J Mon 331, FC13.2.1 Cheng, L Thu 297, Cheng, LS FC10.2.5 Cheng, P-W Tue 146 Cheng, R FC09.3.3 Cheng, W-H Tue 146 Cheng, X Tue 403 Cheng, Wed 402 Cheng, X-R Thu 432, Mon 470 Cheng, Y Mon 467 Cheng, Y-C FC16.5.3 Cheong, SK Thu 379, Thu 380 Cherny, SS Mon 271, Mon 159 Chess-Williams, R Tue 199 Chetan, P Mon 091 Cheung, BMY Mon 271, Mon 159 Cheung, CM Thu 389 Cheung, N Mon 045 Chevet, E FC17.2.5 Chiavaroli, A Mon 105, Wed 329, Wed 434 Chiavegatti, T Wed 054 Chiavegatto, S FC03.1.5 Chiba, Y Mon 303, Mon 304, Tue 234, Tue 259, Mon 272, Tue 265, Tue 287 Chick, J W06.3 Chidiac, P Tue 180 Chien, C-H Mon 158 Chien, W-L Wed 403 Chignalia, AZ Wed 233 Chik, Z Tue 444 Chimienti, F FC05.1.4 Chin, P Tue 322 Chinen, K Thu 344 Ching, P Wed 369 Chiou, L-C Wed 035 Chipashvili, M Wed 272 Chisyaki, A Wed 223 Chitaley, FC08.1.2 Chiu, C-T Thu 283 Chiu, P-H FC17.1.5 Chiu, P-T Mon 423 Chladek, J Wed 017, Tue 342, Tue 125, Thu 168 Chladkova, J Wed 017 Cho, CH W02.1.4, Tue 476, Tue 417 Cho, CWC Wed 330 Cho, G Tue 068 Cho, IH Mon 427 Cho, S Tue 349, Thu 418 Cho, SK Mon 013 Choe, BI Tue 334 Choe, T-B Tue 427 Choi, C-I Mon 049, Mon 065, Mon 066, Mon 069, Mon 358, Mon 359, Tue 044, Tue 043, Tue 073, Tue 350, Tue 161, Tue 162, Tue 323, Tue 324, Tue 332, Tue 333, Wed 143 Choi, J-Y Tue 352 Choonara, I Thu 007 Choong, E Mon 160 Chopard, P Tue 305 Chopra, K Mon 183, Wed 168 Chopra, SC FC01.3.6 Chotewuttakorn, S Thu 335 Chou, SH Tue 135 Choudhary, S W03.2 Choudhury, MR Thu 120 Choudhury, WR Thu 120 Chowdhury, A Tue 097 Christ, G J FC08.3.1 Christakidis, D Mon 187 Christensen, GL Wed 036, Wed 070, Thu 058 Christensen, H Mon 041 Christensen, HR Wed 161, Mon 360 Christensen, KL Mon 200 Christensen, LP Wed 380 Christensen, MMH Mon 050 Christensen, T Mon 320 Christians, U Mon 053 Christiansen, B FC11.5.1 Christiansen, C Mon 346, W26.4, W26.2 Christiansen, S Wed 397 Christie, MJ FC03.3.1 Crsen, N Wed 241 Christopoulos, A Wed 089, Wed 082, Wed 043, Thu 041, Thu 080 FC11.2.2 Index 323
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275: FC16 Natural products: Past and fut
- Page 276 and 277: FC17 New approaches and targets in
- Page 278 and 279: FC17 New approaches and targets in
- Page 280 and 281: W34 State-of-the-art of basic and c
- Page 282 and 283: FC10 Drugs for half the world: Paed
- Page 284 and 285: FC11 G protein-coupled 7TM receptor
- Page 286 and 287: FC11 G protein-coupled 7TM receptor
- Page 288 and 289: FC11 G protein-coupled 7TM receptor
- Page 290 and 291: FC13 Maximising benefits and minimi
- Page 292 and 293: FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375:
372 Index Name Paper ref. Name Pape
- Page 376 and 377:
374 Index Name Paper ref. Name Pape
- Page 378 and 379:
376 Index Name Paper ref. Name Pape
- Page 380 and 381:
378 Index Name Paper ref. Name Pape
- Page 382 and 383:
380 Index Name Paper ref. Name Pape
- Page 384 and 385:
382 Notes Notes
- Page 386:
Final Programme printed in Singapor